Development of Highly Potent, Selective, and Cellular Active Triazolo[1,5-a]pyrimidine-Based Inhibitors Targeting the DCN1-UBC12 Protein-Protein Interaction

被引:59
|
作者
Wang, Shuai [1 ,2 ,6 ,7 ]
Zhao, Lijie [1 ,2 ,6 ,7 ]
Shi, Xiao-Jing [1 ,2 ,6 ,7 ]
Ding, Lina [1 ,2 ,6 ,7 ]
Yang, Linlin [8 ]
Wang, Zhi-Zheng [1 ,2 ,6 ,7 ]
Shen, Dandan [1 ,2 ,6 ,7 ]
Tang, Kai [1 ,2 ,6 ,7 ]
Li, Xiao-Jing [1 ,2 ,6 ,7 ]
Mamun, M. A. A. [1 ,2 ,6 ,7 ]
Li, Huiju [1 ,2 ,6 ,7 ]
Yu, Bin [1 ,2 ,6 ,7 ,9 ]
Zheng, Yi-Chao [1 ,2 ,6 ,7 ]
Wang, Shaomeng [1 ,2 ,3 ,4 ,5 ]
Liu, Hong-Min [1 ,2 ,6 ,7 ]
机构
[1] Zhengzhou Univ, Sch Pharmaceut Sci, Zhengzhou 450001, Henan, Peoples R China
[2] Zhengzhou Univ, Inst Drug Discovery & Dev, Zhengzhou 450001, Henan, Peoples R China
[3] Univ Michigan, Dept Internal Med, 1600 Huron Pkwy, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Dept Pharmacol, 1600 Huron Pkwy, Ann Arbor, MI 48109 USA
[5] Univ Michigan, Dept Med Chem, 1600 Huron Pkwy, Ann Arbor, MI 48109 USA
[6] Coinnovat Ctr Henan Prov New Drug R&D Preclin Saf, Zhengzhou 450001, Henan, Peoples R China
[7] Zhengzhou Univ, Minist Educ China, Key Lab Adv Technol Drug Preparat Technol, Zhengzhou 450001, Henan, Peoples R China
[8] Zhengzhou Univ, Sch Basic Med Sci, Dept Pharmacol, Zhengzhou 450001, Henan, Peoples R China
[9] Nanjing Univ, State Key Lab Pharmaceut Biotechnol, Nanjing 210023, Jiangsu, Peoples R China
基金
中国国家自然科学基金; 国家重点研发计划; 中国博士后科学基金;
关键词
CULLIN-RING LIGASES; NEDD8-ACTIVATING ENZYME; E3; LIGASE; DEGRADATION; NEDDYLATION; DISCOVERY; CARCINOMA; UBIQUITINATION; AMPLIFICATION; PROGRESSION;
D O I
10.1021/acs.jmedchem.9b00113
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The cullin-RING ubiquitin ligases (CRLs) are responsible for about 20% of cellular protein degradation and regulate diverse cellular processes, and the dysfunction of CRLs is implicated in human diseases. Targeting the CRLs has become an emerging strategy for the treatment of human diseases. Herein, we describe the discovery of a hit compound from our in-house library and further structure-based optimizations, which have enabled the identification of new triazolo[1,5-a]pyrimidine-based inhibitors targeting the DCN1-UBC12 interaction. Compound WS-383 blocks the DCN1-UBC12 interaction (IC50 = 11 nM) reversibly and shows selectivity over selected kinases. WS-383 exhibits cellular target engagement to DCN1 in MGC-803 cells. WS-383 inhibits Cul3/1 neddylation selectively over other cullins and also induces accumulation of p21, p27, and NRF2. Collectively, targeting the DCN1-UBC12 interaction would be a viable strategy for selective neddylation inhibition of Cul3/1 and may be of therapeutic potential for disease treatment in which Cul3/1 is dysregulated.
引用
收藏
页码:2772 / 2797
页数:26
相关论文
共 39 条
  • [21] Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-RafV600E kinase with favorable physicochemical and pharmacokinetic properties
    Ren, Li
    Laird, Ellen R.
    Buckmelter, Alex J.
    Dinkel, Victoria
    Gloor, Susan L.
    Grina, Jonas
    Newhouse, Brad
    Rasor, Kevin
    Hastings, Gregg
    Gradl, Stefan N.
    Rudolph, Joachim
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (02) : 1165 - 1168
  • [22] Discovery of Novel [1,2,4]Triazolo[1,5-a]pyrimidine Derivatives as Novel Potent S-Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
    Hu, Kaizhao
    Luo, Yongqiang
    Miao, Peipei
    Zhao, Lidan
    Zhao, Bing
    Shi, Xiao-Jing
    Liu, Hong-Min
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (18) : 16435 - 16454
  • [23] Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor
    Wang, Sai-Qi
    Teng, Qiu-Xu
    Wang, Shuai
    Lei, Zi-Ning
    Hu, Hui-Hui
    Lv, Hui-Fang
    Chen, Bei-Bei
    Wang, Jian-Zheng
    Shi, Xiao-Jing
    Xu, Wei-Feng
    Liu, Hong-Min
    Chen, Xiao-Bing
    Chen, Zhe-Sheng
    Yu, Bin
    ACTA PHARMACEUTICA SINICA B, 2022, 12 (08) : 3263 - 3280
  • [24] Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent,specific and orally active P-glycoprotein(P-gp)inhibitor
    Sai-Qi Wang
    Qiu-Xu Teng
    Shuai Wang
    Zi-Ning Lei
    Hui-Hui Hu
    Hui-Fang Lv
    Bei-Bei Chen
    Jian-Zheng Wang
    Xiao-Jing Shi
    Wei-Feng Xu
    Hong-Min Liu
    Xiao-Bing Chen
    Zhe-Sheng Chen
    Bin Yu
    Acta Pharmaceutica Sinica B, 2022, 12 (08) : 3263 - 3280
  • [25] The Development of Inhibitors Targeting the Mixed Lineage Leukemia 1 (MLL1)-WD Repeat Domain 5 Protein (WDR5) Protein-Protein Interaction
    Ye, Xiaoqing
    Chen, Gang
    Jin, Jia
    Zhang, Binzhong
    Wang, Yinda
    Cai, Zhenhai
    Ye, Fei
    CURRENT MEDICINAL CHEMISTRY, 2020, 27 (33) : 5530 - 5542
  • [26] Peptide structure stabilization by lipidation for development of potent inhibitors of protein-protein interactions: Application for generation of selective IGF1R antagonists
    Johannessen, Liv
    Remsberg, Jarrett
    Tarasov, Sergey
    Jiang, Sheng
    Tarasova, Nadya
    CANCER RESEARCH, 2009, 69
  • [27] Discovery of [1,2,3]triazolo[4,5-d]pyrimidine derivatives as highly potent, selective, and cellularly active USP28 inhibitors
    Liu, Zhenzhen
    Zhao, Taoqian
    Li, Zhonghua
    Sun, Kai
    Fu, Yundong
    Cheng, Ting
    Guo, Jimin
    Yu, Bin
    Shi, Xiaojing
    Liu, Hongmin
    ACTA PHARMACEUTICA SINICA B, 2020, 10 (08) : 1476 - 1491
  • [28] Discovery of [1,2,3]triazolo[4,5-d]pyrimidine derivatives as highly potent, selective, and cellularly active USP28 inhibitors
    Zhenzhen Liu
    Taoqian Zhao
    Zhonghua Li
    Kai Sun
    Yundong Fu
    Ting Cheng
    Jimin Guo
    Bin Yu
    Xiaojing Shi
    Hongmin Liu
    Acta Pharmaceutica Sinica B, 2020, 10 (08) : 1476 - 1491
  • [29] Targeting the Bcl-2/BH3 protein-protein interaction: Identification, design, and synthesis of new selective inhibitors of the Mcl-1/BH3 interaction
    Pernazza, Daniele
    Lawrence, Harshani R.
    Doi, Kenichiro
    Sung, Shen-Shu
    Guida, Wayne C.
    Sebti, Said M.
    Wang, Hong-Gang
    Lawrence, Nicholas J.
    CANCER RESEARCH, 2010, 70
  • [30] Structure-based design, synthesis, and study of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase CK2
    Nie, Zhe
    Perretta, Carin
    Erickson, Philip
    Margosiak, Stephen
    Almassy, Robert
    Lu, Jia
    Averill, April
    Yager, Kraig M.
    Chu, Shaosong
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (15) : 4191 - 4195